Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of baloxavir in combination with oseltamivir in
treating severe influenza infection in patients who have previously received a hematopoietic
(blood) stem cell transplant or have a hematological malignancy. Baloxavir is an antiviral
drug that inhibits the growth of influenza virus, reduces viral load and prevents further
influenza infection. Osetamivir is an antiviral drug that blocks enzymes on the surfaces of
influenza viruses, interfering with cell release of complete viral particles. Giving
baloxavir in combination with oseltamivir may shorten or decrease the intensity of influenza
infection compared to oseltamivir alone.